Schuetz Thomas J. 4

What Happened
Thomas J. Schuetz, CEO of Compass Therapeutics (CMPX), had 36,687 shares withheld by the company on February 8, 2026 to cover tax withholding obligations related to vested restricted stock units (RSUs). The shares were valued at $6.52 each, for a total disposition of approximately $239,199. This was a tax-withholding disposition (transaction code F), not an open‑market sell.

Key Details

• Transaction date and price: 2026-02-08, 36,687 shares at $6.52 per share (total ≈ $239,199).
• Transaction type: F — shares withheld to cover tax withholding on RSU vesting (not a voluntary market sale).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing: Report filed 2026-02-10 for a 2026-02-08 transaction — appears timely (Form 4s are generally due within two business days).
• Footnotes:
  • F1: Confirms shares were withheld by the issuer to satisfy tax withholding obligations.
  • F2: Details unvested RSU awards: 125,000 RSUs granted 2/8/2023 (4-year annual vesting, first vested 2/8/2024); 318,750 RSUs granted 1/9/2024 (4-year annual vesting, first vested 1/9/2025); 250,000 RSUs granted 1/2/2026 (4-year annual vesting, first vest 1/2/2027).

Context
Tax-withholding dispositions are routine when RSUs vest: the company retains (or sells) a portion of the shares to cover withholding rather than the insider selling shares on the open market. This action reflects standard payroll tax treatment of equity compensation and does not necessarily indicate a change in the insider’s view of the company.